August 2026– date –
-
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
GLP-1 Review Finds Strongest Signals for GI Adverse Events, Hints at Reduced Infection/Respiratory Risk
GI and Hepatology News USA Overview A systematic review and meta-analysis published in JAMA Network Open found that GLP-1 receptor agonists (GLP-1 RAs) consistently increase gastrointestinal side effects like nausea, vomiting, and diarrh... -
bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges
bioRxiv USA Overview A bioRxiv preprint introduces a novel 'post-loading' strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to admi... -
Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy
Imperial College London UK Overview Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-spe... -
Bambusa Therapeutics’ Bispecific Antibody BBT001 Achieves Rapid, Durable Itch Relief and AD Improvement in Phase 1 Atopic Dermatitis Trial
Dermatology Times USA Overview Preliminary Phase 1 clinical data for Bambusa Therapeutics' bispecific antibody BBT001 shows rapid and sustained improvement in disease severity and pruritus in moderate-to-severe atopic dermatitis (AD) pat... -
Semaglutide More Than Doubles MASH Resolution Likelihood in Meta-Analysis, Stabilizing Fibrosis
AJMC USA Overview A systematic review and meta-analysis published in Medicine reveals that the GLP-1 receptor agonist semaglutide more than doubles the likelihood of MASH (metabolic dysfunction-associated steatohepatitis) resolution with... -
Sanofi Unveils ‘Dual-Targeting Library 2.0’ to Accelerate Novel Bispecific Therapeutic Design
Sanofi France Overview Sanofi has announced its innovative 'Dual-Targeting Library (DTL) 2.0' approach for designing novel bispecific therapeutics. This strategy combines monospecific antibodies and nanobodies to build extensive bispecif... -
Dove Medical Press Reviews Exosome-Inspired Nanocarriers: Next-Gen Drug Delivery for Cancer Therapy
Dove Medical Press UK Overview Dove Medical Press published a review on exosomes as next-generation bio-derived drug delivery systems for cancer therapy. The review emphasizes exosomes' natural ability to cross biological barriers and th... -
Mapping AI Drug Discovery: Key Players Lead Across Target Identification, Generative Design, and Clinical Optimization
Unknown Global Overview A new article maps the AI drug discovery landscape into four key layers: biological target identification, generative molecule design, automated experimentation, and clinical trial optimization. Recursion Pharmace...
